Cord Blood America CEO Matthew Schissler Details Aggressive Expansion Strategies in U.S. ... (h facilitates umbilical cord blood stem ...)

Cord Blood America CEO Matthew Schissler Details Aggressive Expansion Strategies in U.S. and Europe

Date:7/9/2008

h facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at http://www.corcell.com. For investor information, visit http://www.cordblood-america.com.

CONTACT:

Paul Knopick

E & E Communications

949/707-5365

pknopick@eandecommunications.com

SOURCE Cord Blood America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Specific antagonism lowers blood pressure
2. Restricting Blood Flow May Help Heart Bypass Patients
3. FDA Updates Prescription Guidelines for Blood Thinner
4. Doctors Often Miss High Blood Pressure in Kids
5. Back to School Means Return of School Blood Drives
6. Blood-flow detector software show promise in preventing brain damage
7. FDA Approves New Roche West Nile Virus Blood Screening Test
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Laser blasts viruses in blood
10. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
11. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level

Post Your Comments:

(Date:12/7/2009)... ORLEANS, Dec. 7 Cell Therapeutics, Inc. ... Ruth Pettengell, M.D. of St. George,s Hospital, University ... American Society of Hematology ("ASH") Annual Meeting updated ... 301) clinical trial of pixantrone (the "PIX 301 ... lymphoma ("NHL") patients who have failed 2 ...

(Date:12/6/2009)... Pharmacyclics, Inc. (Nasdaq: PCYC ) ... study showing safety and clinical activity in patients ... with its HDAC inhibitor PCI-24781 as a single ... 51st ASH Annual Meeting being held in New ... is an oral pan-HDAC inhibitor which is currently ...

(Date:12/6/2009)... in virus , , SUNDAY, Dec. 6 (HealthDay News) -- Early ... in a tiger that lived thousands or millions of years ... took on a bit of a tiger,s genetic material, scientists ... virus to this day. That tiger, in fact, may have ... that ultimately led to its infection of humans. , The ...

(Date:12/6/2009)... Dec. 6, 2009 A new study provides welcome ... as venous thromboembolism (VTE). , The condition is ... year, and occurs when an abnormal clot forms in ... pain and swelling. In some cases, the clot may ... the heart to the lungs, causing a potentially fatal ...

(Date:12/5/2009)... 5 There have been significant scientific advances in ... to gain a better understanding of how certain diseases ... provide patients with the best care. Research presented today ... of Hematology explores optimal induction therapies for managing multiple ...

Breaking Medicine News(10 mins):Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2 Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3 Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4 Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5 Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2 Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3 Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4 Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5 Health News:AIDS May Date Back to Ancient Tiger 2 Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2 Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2 Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3 Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4 Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5 Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6 Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7 Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8

[0] Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data [1] Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting [0] AIDS May Date Back to Ancient Tiger [0] New drug shows promise for those with clotting disorders: McMaster researcher [0] New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer

... American Society of Aesthetic Plastic Surgery indicate a ... including injectable treatments like BOTOX® Cosmetic and major ... since collection of the data began in 1997. ... a number of these popular options, and Beverly ...

... 24 World Veterinary Day, April 25, 2009, celebrates ... year,s theme, ,Veterinarians and Livestock Farmers: a ... highlights a discipline of veterinary medicine the AVMA ... W. Ron DeHaven, DVM, MBA, Chief Executive Officer of ...

... Inc. announces the completion of its transformation from a telemedicine device ... , ... North Chelmsford, MA (PRWEB) April 24, 2009 ... to a Telemedicine Encounter Management Systems company. AMD will showcase ...

... how business and medicine can collaborate to solve today,s ... questions regarding the state of collaboration between industry, academia ... how evolving reimbursement practices are changing what it means ... 30, 2009, 3:00 6:45 p.m. , PLACE: , Weill ...

... study finds , , FRIDAY, April 24 (HealthDay News) -- ... disease are taking the recommended combination of medications to ... on 711 people with peripheral artery disease who had ... in 2004. Three years later, 465 of the surviving ...

... the virus is the same that sickened seven people in ... officials took extraordinary steps Friday to try to contain a ... and possibly dozens more, and sickened more than 900 other ... that it could mark the start of a flu pandemic, ...

Other Medicine News:Health News:Beverly Hills Cosmetic Plastic Surgeon Andrew T. Cohen, MD Helping New Moms Restore their Bodies with a Mommy Makeover 2 Health News:Beverly Hills Cosmetic Plastic Surgeon Andrew T. Cohen, MD Helping New Moms Restore their Bodies with a Mommy Makeover 3 Health News:AVMA Celebrates World Veterinary Day 2 Health News:AMD Global Telemedicine Inc. to Unveil New Solutions at ATA 2009 Conference in Las Vegas 2 Health News:With Peripheral Artery Disease, Med Adherence Is Low 2 Health News:At Least 20 Dead, Hundreds Ill in Swine Flu Outbreak in Mexico 2 Health News:At Least 20 Dead, Hundreds Ill in Swine Flu Outbreak in Mexico 3 Health News:At Least 20 Dead, Hundreds Ill in Swine Flu Outbreak in Mexico 4 Health News:At Least 20 Dead, Hundreds Ill in Swine Flu Outbreak in Mexico 5

Beverly Hills Cosmetic Plastic Surgeon Andrew T. Cohen, MD Helping New Moms Restore their Bodies with a Mommy Makeover AVMA Celebrates World Veterinary Day AMD Global Telemedicine Inc. to Unveil New Solutions at ATA 2009 Conference in Las Vegas Weill Cornell and Cornell's Johnson School present first annual business and medicine symposium With Peripheral Artery Disease, Med Adherence Is Low At Least 20 Dead, Hundreds Ill in Swine Flu Outbreak in Mexico

(Date:12/4/2009)... Inc. (NYSE Amex: PIP ), a biodefense company ... today the presentation of new data from the Company,s ... Antigen (rPA) based anthrax vaccine is structurally stable and ... and including 55 degrees C. The data were ...

(Date:12/4/2009)... PharmAthene, Inc. (NYSE Amex: PIP ), ... and chemical threats, announced today that the Company ... effectiveness of Valortim® in an inhalation anthrax model ... The data are being presented during an oral ...

(Date:12/4/2009)... 4 Watson Pharmaceuticals, Inc. (NYSE: WPI ... that its subsidiary, Watson Laboratories, Inc.-Florida, filed an Abbreviated ... Drug Administration seeking approval to market its 8mg ramelteon ... by Takeda Pharmaceutical Company Limited. Watson,s 8mg ramelteon ...

[0] PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop [0] PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop [0] Watson Files FDA Application for Generic Rozerem(R)

... 04, 2007 /PRNewswire-FirstCall/ --,Genta Incorporated announced the ... trial of its marketed product, Ganite(R) (gallium,nitrate ... patients with relapsed or refractory non-Hodgkin's,lymphoma (NHL). ... meeting of,the American Society of Clinical Oncology ...

... Pertuzumab shows promising results in,advanced breast cancer ... BASEL, Switzerland, June 4, 2007-Early clinical results ... medicine pertuzumab, a HER,dimerisation inhibitor, show substantial ... breast cancer, when,combined with Herceptin. The study ...

Other Medicine Technology:Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2 Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3 Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4 Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5 Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 2 Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 3 Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 4 Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 5

Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin

The Charlotte Shoulder™ System address arthroscopic, mini-open and open procedures with time saving instrumentation....

Arthroscopic instrument system for instability and SLAP fixation....

Suture Cutter, straight...

... The Mini-Open Rotator Cuff Repair ... by,reducing procedure time, incision size and ... system,augments other rotator cuff repair systems ... of,three sizes of matched cortical gauge ...

Medicine Products:

Charlotte Shoulder™ System TAG Arthroscopic® Delivery System 3.7 mm Rod II Suture Cutter, straight Mini-Open Rotator Cuff Repair System

Cord Blood America CEO Matthew Schissler Details Aggressive Expansion Strategies in U.S. ...(h facilitates umbilical cord blood stem ...),Health